Bevacizumab Recall: RC Outsourcing intravitreal syringes
Announced 2025-10-15 · FDA
FDA recalls RC Outsourcing Bevacizumab 0.25 mL intravitreal syringes due to lack of assurance of sterility. Approximately 2,669 syringes distributed nationwide in the US for hospital/office use (Rx Only) that require refrigeration are affected. Affected lots include 20250708-768A26, 20250715-944DF2, 20250722-55C603, and 20250722-5DC113 with BUDs Oct 06, Oct 13, and Oct 20, 2025.
| Brand | RC Outsourcing, LLC |
|---|---|
| Product | Bevacizumab 1.75 mg/0.07 mL - 0.25 mL syringe, Intravitreal, 0.07 mL Total Volume, Rx Only, Hospital/Office Use Only, Refrigerate, RC Outsourcing LLC, Lowellville, OH 44436. |
| Reason | Lack of assurance of sterility. |
| Severity | moderate |
| Units affected | 2669 |
| Distribution | Nationwide in the US |
| Agency | FDA |
| Recall / campaign no. | Lot # 20250708-768A26, BUD: Oct 06, 2025 20250715-944DF2 BUD: Oct 13, 2025 20250722-55C603 BUD: Oct 20, 2025 20250722-5DC113 BUD: Oct 20, 2025 |
WHAT YOU SHOULD DO
- Do not use the recalled syringes.
- Quarantine and return or dispose of affected lots: 20250708-768A26; 20250715-944DF2; 20250722-55C603; 20250722-5DC113 (BUDs Oct 06, 13, or 20, 2025).
- Contact the hospital or clinic where you obtained the product for disposal or replacement instructions.
- If you have questions, contact your healthcare provider or the FDA.
This is an automatically maintained record of an official recall notice. Details can change; always follow the official notice linked above. See all records in the Recall Database.